← Back to Search

Organoselenium Compound

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

Phase 2
Waitlist Available
Research Sponsored by Sound Pharmaceuticals, Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 weeks

Summary

This trial is testing SPI-1005 to see if it can protect hearing and improve lung function in cystic fibrosis patients who are being treated with an antibiotic for lung infections. The medication might help prevent ear damage and support better lung health.

Eligible Conditions
  • Ototoxicity
  • Hearing Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in lung function
Distortion Product Otoacoustic Emissions
Sensorineural Hearing Loss (disorder)
+4 more
Secondary study objectives
Pharmacodynamics of Glutathione, cysteine and cystine
Pharmacodynamics of Nrf2
Pharmacogenomics

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: SPI-1005 Ebselen 200mg Capsule x3Experimental Treatment1 Intervention
600mg SPI-1005 bid po x 21d High Dose Arm
Group II: SPI-1005 Ebselen 200mg Capsule x2Experimental Treatment1 Intervention
400mg SPI-1005 bid po x 21d Mid Dose Arm
Group III: SPI-1005 Ebselen 200mg Capsule x1Experimental Treatment1 Intervention
200mg SPI-1005 bid po x 21d Low Dose Arm
Group IV: SPI-1000 Capsule 0mg Ebselen PlaceboPlacebo Group1 Intervention
0mg Ebselen SPI-1000 bid po x 21d
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ebselen
Not yet FDA approved
Ebselen
Not yet FDA approved
Ebselen
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Sound Pharmaceuticals, IncorporatedLead Sponsor
12 Previous Clinical Trials
1,088 Total Patients Enrolled
1 Trials studying Ototoxicity
80 Patients Enrolled for Ototoxicity
Medical University of South CarolinaOTHER
977 Previous Clinical Trials
7,400,947 Total Patients Enrolled
1 Trials studying Ototoxicity
105 Patients Enrolled for Ototoxicity
Cystic Fibrosis FoundationOTHER
197 Previous Clinical Trials
37,530 Total Patients Enrolled
Jonathan Kil, MDStudy ChairSOUND PHARMACEUTICALS, INC.
5 Previous Clinical Trials
532 Total Patients Enrolled
1 Trials studying Ototoxicity
80 Patients Enrolled for Ototoxicity
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top